Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Dogwood Therapeutics (DWTX) and Precision BioSciences (DTIL)

Tipranks - Tipranks - Fri Mar 20, 5:42AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ProKidney (PROK), Dogwood Therapeutics (DWTX) and Precision BioSciences (DTIL) with bullish sentiments.

Claim 70% Off TipRanks Premium

ProKidney (PROK)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on ProKidney, with a price target of $12.00. The company’s shares closed last Wednesday at $2.08.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 16.8% and a 48.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Adlai Nortye Ltd. Sponsored ADR, NewAmsterdam Pharma Company, and XOMA Royalty Corporation. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for ProKidney with a $5.33 average price target.

See today’s best-performing stocks on TipRanks >>

Dogwood Therapeutics (DWTX)

H.C. Wainwright analyst Sean Lee CFA reiterated a Buy rating on Dogwood Therapeutics today and set a price target of $12.00. The company’s shares closed last Wednesday at $2.97, close to its 52-week low of $1.62.

According to TipRanks.com, CFA is a 1-star analyst with an average return of -1.9% and a 28.4% success rate. CFA covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Senseonics Holdings, and Kazia Therapeutics. ;'>

Currently, the analyst consensus on Dogwood Therapeutics is a Moderate Buy with an average price target of $13.50, representing a 335.5% upside. In a report issued on March 6, Maxim Group also maintained a Buy rating on the stock with a $15.00 price target.

Precision BioSciences (DTIL)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Precision BioSciences, with a price target of $60.00. The company’s shares closed last Wednesday at $7.03.

According to TipRanks.com, Trucchio is a 5-star analyst with an average return of 23.9% and a 46.0% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Arrowhead Pharmaceuticals, and Alto Neuroscience, Inc. ;'>

Precision BioSciences has an analyst consensus of Strong Buy, with a price target consensus of $36.33, implying a 428.1% upside from current levels. In a report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $30.00 price target.

Read More on PROK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).